echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Patients with multiple sclerosis show strong T cell responses to mRNA COVID-19 vaccine

    Patients with multiple sclerosis show strong T cell responses to mRNA COVID-19 vaccine

    • Last Update: 2021-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    New research shows that multiple sclerosis (MS) patients receiving anti-cd20 (aCD20) treatment can produce a strong T cell response to the mRNA COVID-19 vaccine, despite the silent antibody response to the vaccine


    Because B cells are responsible for the production of antibodies, when B cells are depleted by aCD20 treatment, the patient's ability to produce antibodies to prevent viruses from entering and infecting human cells is significantly weakened


    "The message from this study is clear-it is worthwhile for MS patients to receive aCD20 treatment and COVID-19 vaccine to prevent serious illness," corresponding author E.


    The study measured the antibody and T cell responses of 20 MS patients treated with aCD20 and compared them with a group of healthy controls


    All healthy control subjects produced anti-spike and anti-receptor binding domain (RBD) antibodies after the first dose of mRNA vaccine, and the antibody level further increased after the second dose


    The time of the patient's last injection of aCD20—usually every six months—plays an important role in the increase in immune response


    "This data not only reveals that patients receiving anti-CD20 injections are still able to develop an important COVID-19 vaccine response, which may protect them from serious diseases, but it also provides information for our clinical practice, telling us how This type of therapy is recommended for patients with multiple sclerosis and other autoimmune diseases


    The researchers found that the T cell subsets of patients treated with aCD20 responded to the vaccine similarly to healthy controls


    "Usually we test for the presence of antibodies when determining whether a patient has an appropriate response to the mRNA vaccine, but this method ignores the immune response of the patient's entire arm," Sokratis a, a researcher in the Department of Rheumatology and one of the main authors of the study Said Apostolidis, MD


    The researchers did notice that because patients receiving aCD20 treatment have a limited antibody response, they may not be able to quickly neutralize the virus before it infects other cells, which may cause them to become infectious carriers of the virus for a longer period of time



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.